253 related articles for article (PubMed ID: 26384300)
1. Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression.
Skrzypek K; Kusienicka A; Szewczyk B; Adamus T; Lukasiewicz E; Miekus K; Majka M
Oncotarget; 2015 Oct; 6(31):31378-98. PubMed ID: 26384300
[TBL] [Abstract][Full Text] [Related]
2. The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation.
Miekus K; Lukasiewicz E; Jarocha D; Sekula M; Drabik G; Majka M
Cell Death Dis; 2013 Jan; 4(1):e459. PubMed ID: 23328666
[TBL] [Abstract][Full Text] [Related]
3. The Proprotein Convertase Furin Contributes to Rhabdomyosarcoma Malignancy by Promoting Vascularization, Migration and Invasion.
Jaaks P; D'Alessandro V; Grob N; Büel S; Hajdin K; Schäfer BW; Bernasconi M
PLoS One; 2016; 11(8):e0161396. PubMed ID: 27548722
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of rhabdomyosarcoma's metastatic behavior through downregulation of MET receptor signaling.
Lukasiewicz E; Miekus K; Kijowski J; Drabik G; Wilusz M; Bobis-Wozowicz S; Majka M
Folia Histochem Cytobiol; 2009 Jan; 47(3):485-9. PubMed ID: 20164036
[TBL] [Abstract][Full Text] [Related]
5. Impaired Wnt signaling in embryonal rhabdomyosarcoma cells from p53/c-fos double mutant mice.
Singh S; Vinson C; Gurley CM; Nolen GT; Beggs ML; Nagarajan R; Wagner EF; Parham DM; Peterson CA
Am J Pathol; 2010 Oct; 177(4):2055-66. PubMed ID: 20829439
[TBL] [Abstract][Full Text] [Related]
6. MET/ERK2 pathway regulates the motility of human alveolar rhabdomyosarcoma cells.
Otabe O; Kikuchi K; Tsuchiya K; Katsumi Y; Yagyu S; Miyachi M; Iehara T; Hosoi H
Oncol Rep; 2017 Jan; 37(1):98-104. PubMed ID: 27840956
[TBL] [Abstract][Full Text] [Related]
7. c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations.
Otte A; Rauprich F; von der Ohe J; Yang Y; Kommoss F; Feuerhake F; Hillemanns P; Hass R
Oncotarget; 2015 Oct; 6(31):31640-58. PubMed ID: 26436697
[TBL] [Abstract][Full Text] [Related]
8. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
[TBL] [Abstract][Full Text] [Related]
9. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy.
Jankowski K; Kucia M; Wysoczynski M; Reca R; Zhao D; Trzyna E; Trent J; Peiper S; Zembala M; Ratajczak J; Houghton P; Janowska-Wieczorek A; Ratajczak MZ
Cancer Res; 2003 Nov; 63(22):7926-35. PubMed ID: 14633723
[TBL] [Abstract][Full Text] [Related]
10. Retinoic acid fails to induce cell cycle arrest with myogenic differentiation in rhabdomyosarcoma.
Al-Tahan A; Sarkis O; Harajly M; Baghdadi OK; Zibara K; Boulos F; Dighe D; Kregel S; Bazarbachi A; El-Sabban M; Skapek SX; Saab R
Pediatr Blood Cancer; 2012 Jun; 58(6):877-84. PubMed ID: 21755593
[TBL] [Abstract][Full Text] [Related]
11. SNAIL is a key regulator of alveolar rhabdomyosarcoma tumor growth and differentiation through repression of MYF5 and MYOD function.
Skrzypek K; Kusienicka A; Trzyna E; Szewczyk B; Ulman A; Konieczny P; Adamus T; Badyra B; Kortylewski M; Majka M
Cell Death Dis; 2018 May; 9(6):643. PubMed ID: 29844345
[TBL] [Abstract][Full Text] [Related]
12. SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma.
Coda DM; Lingua MF; Morena D; Foglizzo V; Bersani F; Ala U; Ponzetto C; Taulli R
Cell Cycle; 2015; 14(9):1389-402. PubMed ID: 25644430
[TBL] [Abstract][Full Text] [Related]
13. SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma.
Saini M; Verma A; Mathew SJ
Cell Death Dis; 2018 Feb; 9(2):237. PubMed ID: 29445192
[TBL] [Abstract][Full Text] [Related]
14. The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma.
Mohamed A; Sun C; De Mello V; Selfe J; Missiaglia E; Shipley J; Murray GI; Zammit PS; Wackerhage H
J Pathol; 2016 Sep; 240(1):3-14. PubMed ID: 27184927
[TBL] [Abstract][Full Text] [Related]
15. Selective upregulation of interleukin-8 by human rhabdomyosarcomas in response to hypoxia: therapeutic implications.
Wysoczynski M; Shin DM; Kucia M; Ratajczak MZ
Int J Cancer; 2010 Jan; 126(2):371-81. PubMed ID: 19588509
[TBL] [Abstract][Full Text] [Related]
16. FOXM1 expression in rhabdomyosarcoma: a novel prognostic factor and therapeutic target.
Kuda M; Kohashi K; Yamada Y; Maekawa A; Kinoshita Y; Nakatsura T; Iwamoto Y; Taguchi T; Oda Y
Tumour Biol; 2016 Apr; 37(4):5213-23. PubMed ID: 26553361
[TBL] [Abstract][Full Text] [Related]
17. miR-942 promotes cancer stem cell-like traits in esophageal squamous cell carcinoma through activation of Wnt/β-catenin signalling pathway.
Ge C; Wu S; Wang W; Liu Z; Zhang J; Wang Z; Li R; Zhang Z; Li Z; Dong S; Wang Y; Xue Y; Yang J; Tan Q; Wang Z; Song X
Oncotarget; 2015 May; 6(13):10964-77. PubMed ID: 25844602
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo.
Raimondi L; Ciarapica R; De Salvo M; Verginelli F; Gueguen M; Martini C; De Sio L; Cortese G; Locatelli M; Dang TP; Carlesso N; Miele L; Stifani S; Limon I; Locatelli F; Rota R
Cell Death Differ; 2012 May; 19(5):871-81. PubMed ID: 22117196
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis.
Belyea BC; Naini S; Bentley RC; Linardic CM
Clin Cancer Res; 2011 Dec; 17(23):7324-36. PubMed ID: 21948088
[TBL] [Abstract][Full Text] [Related]
20. LEF1 reduces tumor progression and induces myodifferentiation in a subset of rhabdomyosarcoma.
Dräger J; Simon-Keller K; Pukrop T; Klemm F; Wilting J; Sticht C; Dittmann K; Schulz M; Leuschner I; Marx A; Hahn H
Oncotarget; 2017 Jan; 8(2):3259-3273. PubMed ID: 27965462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
